Revvity Inc
Research Revvity Inc (RVTY) on Bullrun: valuation model: 25.7% overvalued, market cap USD 17.20B, P/E 73.2, dividend yield 0.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRVTY
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Valuation signal25.7% overvalued
- Market capUSD 17.20B
- P/E73.2
- Dividend yield0.2%
- Financial periodQ2 2026
- RevenueUSD 711.12M
- Net incomeUSD 40.72M
- Free cash flowUSD 95.46M
- Gross margin54.5%
Valuation Snapshot
Bullrun's latest valuation model marks Revvity Inc as 25.7% overvalued; latest market cap is USD 17.20B; P/E is 73.2; dividend yield is 0.2%.
Peer valuation comparison
Latest P/E is 73.22x versus a Healthcare sector median of 24.61x (197.6% above).
Latest dividend yield is 0.18% versus a Healthcare sector median of 1.84% (90.2% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.86B | USD 241.20M | USD 509.41M | 54.8% | 2.07 | USD 919.86M | USD 3.22B | USD 7.25B |
| FY2024 | USD 2.76B | USD 270.39M | USD 541.65M | 55.8% | 2.2 | USD 1.16B | USD 3.15B | USD 7.67B |
| FY2023 | USD 2.75B | USD 693.09M | USD 9.90M | 72.3% | 5.55 | USD 913.16M | USD 3.90B | USD 7.87B |
| FY2022 | USD 3.83B | USD 943.16M | USD 1.32B | 63.6% | 8.08 | USD 603.32M | USD 4.98B | USD 7.14B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 17.20B | 73.2 | 0.2% | 0.28 |
| 2025 | 2025-12-31 | USD 10.86B | 46.3 | 0.3% | 0.28 |
| 2024 | 2024-12-31 | USD 13.47B | 46.3 | 0.3% | 0.28 |
| 2023 | 2023-12-29 | USD 13.49B | 18.4 | 0.3% | 0.28 |
| 2022 | 2022-12-30 | USD 17.71B | 28.9 | 0.2% | 0.28 |
| 2021 | 2021-12-31 | USD 25.37B | 25.1 | 0.1% | 0.28 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.28 USD, yield 0.2%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.28 USD |
| FY2024 | 0.28 USD |
| FY2023 | 0.28 USD |
| FY2022 | 0.28 USD |
About Revvity Inc
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
ETFs that hold Revvity Inc
Revvity Inc is one of the ten largest holdings of 9 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| iShares S&P 500 Equal Weight UCITS ETF USD (Acc) | 0.25% | 0.15% |
| iShares Healthcare Innovation UCITS ETF USD (Acc) | 1.73% | 0.40% |
| Amundi S&P 500 Equal Weight ESG UCITS ETF Acc | 0.41% | 0.18% |
| Invesco S&P 500 Equal Weight Index ETF Acc | 0.25% | 0.20% |
| iShares S&P 500 Equal Weight UCITS ETF GBP Hedged (Acc) | 0.25% | 0.17% |
| Amundi S&P 500 Equal Weight ESG UCITS ETF EUR Hedged Acc | 0.41% | 0.20% |
| iShares S&P 500 Equal Weight UCITS ETF EUR Hedged (Acc) | 0.25% | 0.17% |
| Invesco S&P 500 Equal Weight Index ETF Inc | 0.25% | 0.20% |
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Revvity Inc overvalued or undervalued?
Bullrun's valuation model currently marks Revvity Inc as 25.7% overvalued.
What is Revvity Inc's market cap?
Revvity Inc's market capitalization is USD 17.20B.
What is Revvity Inc's P/E ratio?
Revvity Inc's price-to-earnings (P/E) ratio is 73.2.
Does Revvity Inc pay a dividend?
Revvity Inc has a dividend yield of 0.2%.
What does Revvity Inc do?
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.